Document is current
Any future updates will be listed below
-
Authors
Izumi, Motohiro
Fujii, Masanori
Kobayashi, Ikei S.
Ho, Vivian
Kashima, Yukie
Udagawa, Hibiki
Costa, Daniel B. https://orcid.org/0000-0002-0689-395X
Kobayashi, Susumu S. https://orcid.org/0000-0003-2262-4001
- License Information
-
More Information
Article History
Received: 27 March 2024
Revised: 19 July 2024
Accepted: 22 July 2024
First Online: 9 August 2024
Competing interests
: The authors declare the following financial interests/personal relationships which may be considered potential competing interests: H.U. reports grants or contracts from Takeda, Boehringer Ingelheim, and Taiho; personal fees (honoraria) from Novartis, Taiho, Chugai, MSD, AstraZeneca, Daiichisankyo. S.S.K. reports research support from Boehringer Ingelheim, MiRXES, Johnson&Johnson, and Taiho Therapeutics, as well as personal fees (honoraria) from AstraZeneca, Boehringer Ingelheim, Bristol Meyers Squibb, Chugai Pharmaceutical, and Takeda Pharmaceuticals, plus royalties from Life Technologies; all interests are outside the submitted work. D.C. reports receiving consulting fees and honoraria from Takeda/Millennium Pharmaceuticals, AstraZeneca, Pfizer, Blueprint Medicines, and Janssen; institutional research support from Takeda/Millennium Pharmaceuticals, AstraZeneca, Pfizer, Merck Sharp and Dohme, Merrimack Pharmaceuticals, Bristol Myers Squibb, Clovis Oncology, Spectrum Pharmaceuticals, Tesaro, Taiho Pharmaceutical Company, and Daiichi Sankyo; and consulting fees from Teladoc and Grand Rounds by Included Health plus royalties from Life Technologies; all interests are outside the submitted work. The remaining authors declare no competing interests.
